PGGHG

Across TCGA pan-cancer cohorts, PGGHG mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PGGHG data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PGGHG mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PGGHG expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

PDAC, LUAD, and GBM are the cancer types where PGGHG mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.325	0.679	.002	24	view →
LUAD	DFS	Tertile	III,IV	0.304	0.875	.011	11	view →
GBM	DFS	Quartile	All	0.247	0.512	<.001	6	view →
UCEC	DFS	Quartile	III,IV	1.000	0.452	.040	4	view →
HNSC	DFS	Median	III,IV	0.939	1.000	.043	1	view →
LSCC	DFS	Median	II,III,IV	0.861	0.970	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PGGHG–PDAC (DFS)

Open the PDAC breakdown →